116 related articles for article (PubMed ID: 38288635)
21. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.
Zhang Y; Wang L; Li Y; Pan Y; Wang R; Hu H; Li H; Luo X; Ye T; Sun Y; Chen H
Onco Targets Ther; 2014; 7():567-73. PubMed ID: 24748806
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of the IASLC grading system of lung adenocarcinoma: a systematic review and meta-analysis.
Hegedűs F; Zombori-Tóth N; Kiss S; Lantos T; Zombori T
Histopathology; 2024 Jul; 85(1):51-61. PubMed ID: 38485464
[TBL] [Abstract][Full Text] [Related]
24. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.
Berntsson J; Eberhard J; Nodin B; Leandersson K; Larsson AH; Jirström K
Oncoimmunology; 2018; 7(8):e1465165. PubMed ID: 30221062
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
26. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Ma J; Chi D; Wang Y; Yan Y; Zhao S; Liu H; Jing J; Pu H; Zhang M
J Cancer; 2018; 9(19):3489-3499. PubMed ID: 30310505
[No Abstract] [Full Text] [Related]
28. Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.
Chen J; Li H; Pang R; Huang J
Onco Targets Ther; 2017; 10():2003-2007. PubMed ID: 28435290
[TBL] [Abstract][Full Text] [Related]
29. Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management.
Mikubo M; Tamagawa S; Kondo Y; Hayashi S; Sonoda D; Naito M; Shiomi K; Ichinoe M; Satoh Y
Lung Cancer; 2024 Jan; 187():107445. PubMed ID: 38157805
[TBL] [Abstract][Full Text] [Related]
30. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
31. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
32. Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer.
Steiniche T; Georgsen JB; Meldgaard P; Deitz AC; Ayers M; Pietanza MC; Zu K
Front Oncol; 2023; 13():1225820. PubMed ID: 38269020
[TBL] [Abstract][Full Text] [Related]
33. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Lee SE; Kim YJ; Sung M; Lee MS; Han J; Kim HK; Choi YL
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561631
[TBL] [Abstract][Full Text] [Related]
34. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1-N2 epidermal growth factor receptor mutant lung adenocarcinoma.
Isaka T; Miyagi Y; Yokose T; Saito H; Kasajima R; Watabe K; Shigeta N; Kikunishi N; Shigefuku S; Murakami K; Adachi H; Nagashima T; Ito H
Transl Lung Cancer Res; 2023 Oct; 12(10):2001-2014. PubMed ID: 38025811
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
36. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.
Fu X; Liu Z; Xiang L; Liu M; Zheng X; Wang J; Liu N; Gao H; Jiang A; Yang Y; Liang X; Ruan Z; Tian T; Yao Y
Cancer Manag Res; 2020; 12():10939-10948. PubMed ID: 33154673
[TBL] [Abstract][Full Text] [Related]
38. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
[TBL] [Abstract][Full Text] [Related]
39. Association between
Zhao L; Liu J; Wang H; Shi J
Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
[TBL] [Abstract][Full Text] [Related]
40. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Inamura K; Yokouchi Y; Sakakibara R; Kobayashi M; Subat S; Ninomiya H; Nagano H; Nomura K; Okumura S; Ishikawa Y
Jpn J Clin Oncol; 2016 Oct; 46(10):935-941. PubMed ID: 27511990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
